Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-126843 · Präparat HOS-096317
Constipation Dyspepsia Abdominal pain Skin and subcutaneous Alopecia tissue disorders Rash Nail disorder Pruritus Dry skin Musculoskeletal and Myalgia connective tissue disorders Arthralgia Pain in extremity General disorders and Mucosal inflammation Chills administration site Oedema peripheral Pain conditions Pyrexia Oedema Fatigue Asthenia ^ Table 2 shows pooled data from the overall treatment period in CLEOPATRA (data cutoff 11 February 2014; median number of cycles of Perjeta was 24); and from the neoadjuvant treatment period in NEOSPHERE (median number of cycles of Perjeta was 4, across all treatment arms) and TRYPHAENA (median number of cycles of Perjeta was 3 – 6 across treatment arms) and from the treatment period of APHINITY (median number of cycles of Perjeta was 18).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage 85432288bf262252f3742f29eef0dc6f080e7d13cfdb06985c52a234a61e08b6 · Zeichen 4869–6087 im Abschnitt